Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects (Q38141840)

29 August 2017

Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects (English)

1 reference

29 August 2017

0 references

1 reference

ChEBI release 2020-05-28

2

Ralf Gold

1 reference

29 August 2017

Ralf A Linker

1

1 reference

29 August 2017

1 November 2013

1 reference

Current Neurology and Neuroscience Reports

29 August 2017

1 reference

29 August 2017

13

1 reference

29 August 2017

394

1 reference

29 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-013-0394-8

29 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Pharmacokinetics of oral fumarates in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Inhibition of dendritic cell differentiation by fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

A genomic screen for activators of the antioxidant response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Effects of dimethyl fumarate on neuroprotection and immunomodulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: Implications for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0394-8

The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network

21 January 2018

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study

1 reference

12 December 2020

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Radical changes in multiple sclerosis pathogenesis

1 reference

12 December 2020

The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1

1 reference

12 December 2020

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

1 reference

12 December 2020

Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis

1 reference

12 December 2020

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

1 reference

12 December 2020

Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis?

1 reference

12 December 2020

[Treatment of psoriasis vulgaris.]

1 reference

12 December 2020

PML in a patient treated with fumaric acid

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference

1 reference

12 December 2020

Manufacturer's response to case reports of PML

1 reference

12 December 2020

BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

10.1007/S11910-013-0394-8

Identifiers

DOI

1 reference

PubMed ID

24061646

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

24061646